Development of immunotherapy for lung adenocarcinoma using XAGE1 antigen and serum antibody as biomarkers

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09235
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Kawasaki Medical School
• Principal Investigator: Oka Mikio 川崎医科大学, 医学部, 教授 (40223995)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 肺がん / がん精巣抗原 / がん免疫 / がん免疫療法 / 予後因子 / 免疫チェックポイント / 抗体療法 / 個別化医療

Outline of Final Research Achievements

Firstly, relationship between immune-related molecules and prognosis was investigated in 120 lung adenocarcinoma tissues, resulted in independent poor prognostic factors of XAGE1 expression and negative T-cell infiltration. Then, the formula predicting their prognosis was created by cluster classification using tumor PD-L1, galectin-9, and XAGE1 antigen expression, and T-cell infiltration, and it almost accurately predicted their prognosis.
Secondly, we found that XAGE1 antigen was expressed in approximately 50% of lung adenocarcinomas and that it’s antibody was detected in almost half of those with XAGE1 antigen. As one reason for negative XAGE1antibody in lung adenocarcinomas with XAGE1 antigen, regulatory T-cell and B-cell infiltrate into tumor site.
Thirdly, we found a bio marker predicting response to immunotherapy in non-small cell lung cancer and applied the patent (#2017-094986) in Japan, however; the biomarker cannot be open here because of submitting its paper.

Free Research Field

がん免疫療法